Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,454 | 301 | 1,150 |
| Samples | 488 | 125 | 361 |
| Peptides | 346 | 82 | 294 |
Function
PSG6 · Pregnancy specific beta-1-glycoprotein 6
This gene is a member of the pregnancy-specific glycoprotein (PSG) gene family. The PSG genes are a subgroup of the carcinoembryonic antigen (CEA) family of immunoglobulin-like genes, and are found in a gene cluster at 19q13.1-q13.2 telomeric to another cluster of CEA-related genes. The PSG genes are expressed by placental trophoblasts and released into the maternal circulation during pregnancy, and are thought to be essential for maintenance of normal pregnancy. The protein encoded by this gene contains the Arg-Gly-Asp tripeptide associated with cellular adhesion and recognition. Alternative splicing results in multiple transcript variants and protein isoforms. [provided by RefSeq, Jul 2012].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 306 amino-acid changes on canonical ENST00000187910 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PSG6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PSG6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Melanoma | 15/210 7% | 79/1899 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 32/1390 2% |
| Endometrial Carcinoma | 2/42 5% | 14/612 2% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 14/810 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Bladder Carcinoma | 1/58 2% | 16/956 2% |
| Other Solid Cancers | 4/94 4% | 20/1515 1% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Colorectal Carcinoma | 11/143 8% | 38/3239 1% |
| Ewings Sarcoma | 4/63 6% | 0/262 0% |
| Gastric Carcinoma | 4/74 5% | 18/1809 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Cervical Carcinoma | 2/35 6% | 3/422 1% |
| Hepatocellular Carcinoma | 3/46 7% | 21/2210 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 6/752 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Pancreatic Carcinoma | 7/89 8% | 7/1611 0% |
| Breast Carcinoma | 3/144 2% | 21/3264 1% |
| Neuroendocrine Tumour | 5/154 3% | 0/577 0% |
| Head and Neck Carcinoma | 2/85 2% | 9/1574 1% |
| Other Sarcomas | 5/69 7% | 0/699 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 14/2550 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Neuroblastoma | 3/87 3% | 4/1331 0% |
Mutation Distribution
Where PSG6 is mutated · all tissues, split by cell line vs tissue
How many mutations in PSG6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 4 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,454 mutations in PSG6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|